Systemic Pre-Treatment With a Group II mGlu Agonist, LY379268, Reduces Hyperalgesiain Vivo

British Journal of Pharmacology - United States
doi 10.1038/sj.bjp.0704583
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Altered Object Exploration but Not Temporal Order Memory Retrieval in an Object Recognition Test Following Treatment of Rats With the Group II Metabotropic Glutamate Receptor Agonist LY379268

Neuroscience Letters
Neuroscience
2014English

Pre-Treatment With Mesenchymal Stem Cells Reduces Ventilator-Induced Lung Injury

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2012English

A Combined Opiate Agonist and Antagonist Treatment Reduces Prolactin Secreting Pituitary Tumor Growth

Journal of Cell Communication and Signaling
BiochemistryCell BiologyMolecular Biology
2017English

Multiple Family Group Treatment Reduces Distress for Caregivers of People With Schizophrenia

Evidence-Based Mental Health
PsychiatryMental Health
2004English

Treatment With TO901317, a Synthetic Liver X Receptor Agonist, Reduces Brain Damage and Attenuates Neuroinflammation in Experimental Intracerebral Hemorrhage

Journal of Neuroinflammation
Molecular NeuroscienceNeurologyImmunologyCellularNeuroscience
2016English

A Developed STING Agonist Has Systemic Antitumor Activity

Cancer Discovery
Oncology
2018English

Clinical Features and Treatment of Pre-Ulcerative Buruli Lesions: REPORT II OF THE UGANDA BURULI GROUP

BMJ
1970English

Class I and II Histone Deacetylase Inhibition by ITF2357 Reduces SLE Pathogenesis in Vivo

Clinical Immunology
AllergyImmunology
2014English

Enhanced Sensitivity to Group II mGlu Receptor Activation at Corticostriatal Synapses in Mice Lacking the Familial Parkinsonism-Linked Genes PINK1 or Parkin

Experimental Neurology
Developmental NeuroscienceNeurology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy